contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
      researchContent {
        title
        lang
        pdfUrl
        relatedContent {
          __typename
          ...PublishingDetails
          ...Reactions
          id
        }
        content {
          title
          lang
          htmlBody
          publishedAt
          createdAt
          changedAt
          isOutdated
          isPremium
        }
      }
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


publication-of-biohit-oyj-remuneration-report-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Hi, it is indeed a significant authorization. The last time there was a slightly larger authorization was likely in 2022, which was related to the Hefei distribution agreement and the share pledge. This can certainly have a significant impact on shareholders, but insider matters are insider matters, and understandably, not everything can be communicated in advance. So, we’ll likely just have to wait and see if/when more information becomes available…

@Antti_Siltanen I would be interested to know what this directed issue of 5,000,000 shares decided by Biohit is related to? It has a major impact on shareholders, yet no one is saying anything (does Biohit not care about its shareholders, etc.?)

And then the final, most important question: At what price?

The notice of the Annual General Meeting seeks authorization for the Board to issue a fairly large number of shares. I wonder if there is already something in the works, or what this might be about? There haven’t been authorizations like that in previous years.

Here are Antti’s comments on Biohit’s latest good news  Biohit announced on Tuesday a new peer-reviewed study, the results of which supported the company’s value proposition regarding the benefit of the GastroPanel test in gastric cancer risk stratification and shortening treatment queues. The research results provide the company with important scientific evidence to support sales and marketing, which is crucial particularly in new market areas and public healthcare projects. The study is based on a project conducted in Chile, which has already led to the implementation of GastroPanel as part of a national cancer prevention strategy.                   Inderes – 22 Apr 26              Tutkimus: Biohitin GastroPanel lyhensi hoitojonoja - Inderes    Endoskopiajonot lyhenivät 87 prosentilla.

Nasdaq Company News              Vertaisarvioitu tutkimus vahvistaa GastroPanel®-testin arvon...                               Peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy queues A new peer-reviewed publication in the prestigious Helicobacter journal (2026) confirms the clinical utility of the GastroPanel® test as a non-invasive triage tool for gastric cancer risk stratification. GastroPanel® combines a biomarker-based test with risk algorithms, enabling safe prioritization of patients for endoscopy and reducing unnecessary procedures. In a practical implementation in Chile (Molina), the method led to an 87% reduction in endoscopy queues and ensured rapid access to endoscopy for high- and medium-risk patients. “This is a very significant milestone for Biohit and healthcare systems worldwide,” says Jussi Hahtela, CEO of Biohit Oyj. “We now have peer-reviewed evidence that endoscopy queues can be reduced by up to 87% without compromising patient safety. The scarcity of healthcare resources is a global challenge, and GastroPanel® offers a practical, evidence-based solution for more efficient resource allocation and improving early detection of gastric cancer.” The results strengthen the position of the GastroPanel® test as a scalable and evidence-based solution for promoting early detection of gastric cancer and for more efficient allocation of healthcare resources worldwide.

Warning: this post is pure speculation and irresponsible doom-mongering. I don’t actually have any idea what the most likely outcome will be. It could go well or very badly​ I can’t say anything more specific regarding the need for cash or possible share issues, but I personally consider the Hefei and China business operations to be the greatest risk. There are €7.5 million in receivables from Hefei, against which there is a pledge of 1.5 million B-shares (value approx. €4.5 million). The matter is further complicated by the fact that Hefei is Biohit’s second-largest owner (over 20% of shares and votes) and, additionally, China is Biohit’s most important market (Asia accounted for nearly half of the revenue in 2025), the distribution of which is handled by Hefei. One can then wonder what happens if Hefei, for one reason or another, gets into financial difficulties and is at risk of total collapse. Or what if Hefei is nationalized in the name of China’s public health​ The receivables would go unpaid, the pledge could be liquidated, but at what price if the distributor for the most important market collapses? In that case, would Hefei also sell the rest of its holdings at a fire-sale price to the other major owner? Quite many other things could also go wrong related to this. The problem and risk simply culminate in the fact that, from the outside, a private investor has no way of assessing the probabilities of these options.

Biohit

Biohit Oyj Remuneration Report March 18, 2026 at 9:30 am local time (EET)Biohit Oyj’s Remuneration Report for the Governing Bodies is published today in PDF format. The Remuneration Report for...

<p>Biohit Oyj Remuneration Report March 18, 2026 at 9:30 am local time (EET)</p><p>Biohit Oyj’s Remuneration Report for the Governing Bodies is published today in PDF format. The Remuneration Report for the Governing Bodies is attached to this stock exchange release and also available at&nbsp;<a href="https://investors.biohithealthcare.com/en/investors/corporate_governance/remuneration">Biohit (biohithealthcare.com)</a></p><p><strong>Additional information:</strong></p><p>CEO&nbsp;Jussi Hahtela, Biohit Oyj<br>tel. +358 9 773&nbsp;861<br><a href="mailto:investor.relations@biohit.fi">investor.relations@biohit.fi</a><br><a href="https://www.biohithealthcare.com/en/">www.biohithealthcare.com</a></p><p><em>Biohit in brief</em></p><p><em>Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.&nbsp;</em><a href="https://www.globenewswire.com/Tracker?data=c5rWyQltbzVNETEAzPUZ5WLkdGhFEQ1oTBo35iEHNX8xhFJ8UXxKcBfwNUj1oaJLkJWDIfhT0_qN_43uOPrHsIIWy25pE_7iX8aTY-nisGmlggNS87UH1ViJkQ-0ezca"><em>www.biohithealthcare.com</em></a></p>      <div>        <hr>        <div><strong>Attachments</strong></div>        <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/biohit/attachments/d6cbffe7-8def-4028-85b9-30da435fcebb/biohit-oyj-remuneration-report-2025.pdf">Biohit Oyj Remuneration Report 2025.pdf</a></div>      </div>

Publication of Biohit Oyj Remuneration Report 2025

Publication of Biohit Oyj Remuneration Report 2025